论文部分内容阅读
目的观察小剂量尿激酶治疗进展性脑梗死的疗效。方法将80例进展性脑梗死患者随机分为2组,治疗组和对照组。2组给予阿司匹林片100 mg,1次/d,奥扎格雷钠注射液80 mg,2次/d抗血小板聚集,及活血化瘀、脑保护等治疗,治疗组在对照组的基础上接受小剂量尿激酶治疗,尿激酶30万U加入250 ml0.9%氯化钠注射液静脉滴注,1次/d,连用3~5 d。对2组治疗前、治疗后5 d、14 d神经功能缺损程度评分。结果治疗14 d后2组神经功能缺损评分比较治疗组差异有统计学意义(P<0.01)。临床疗效比较,治疗组显效率55%和有效率80%明显高于对照组(P<0.05,P<0.05),差异有统计学意义,且无明显副反应。结论小剂量尿激酶治疗进展性脑梗死有效、安全、可靠。
Objective To observe the therapeutic effect of low-dose urokinase on patients with progressive cerebral infarction. Methods 80 patients with progressive cerebral infarction were randomly divided into two groups, the treatment group and the control group. Two groups were treated with Aspirin 100 mg once daily, Ozagrel Sodium 80 mg twice daily, anti-platelet aggregation, and blood circulation and brain protection. The treatment group received small Urokinase treatment, urokinase 300 000 U 250 ml 0.9% sodium chloride injection intravenous infusion, 1 / d, once every 3 ~ 5 d. The scores of neurological impairment before treatment, 5 days and 14 days after treatment were evaluated in two groups. Results After 14 days of treatment, the difference of neurological deficit score between the two groups was statistically significant (P <0.01). Compared with the control group, the effective rate and the effective rate of 55% and 80% of the treatment group were significantly higher than those of the control group (P <0.05, P <0.05). The difference was statistically significant and no obvious side effects. Conclusion Low-dose urokinase is effective, safe and reliable for the treatment of progressive cerebral infarction.